[ad_1]
KUALA LUMPUR: The Ministry of Science, Technology and Innovation (MOSTI) through the National Biotechnology Institutes of Malaysia (NIBM) has signed a Letter of Intent (LOI) with the Embassy of Russia here for more information on the Covid-19 vaccine, Sputnik V.
His Deputy Minister, Ahmad Amzad Hashim, said that Russia’s Direct Investment Fund (RDIF) had acquired the exclusive rights to supply the Sputnik V vaccine to the world.
“Sputnik V is developed by the Gamaleya National Research Center for Epidemiology and Microbiology, the agency that developed the Middle East respiratory syndrome (MERS) vaccine.
“Phase 3 of the Sputnik V clinical trial is expected to involve participants from around the world. More talks will be held here soon with the Russian Embassy here about the vaccine. “
Ahmad Amzad said this in Dewan Negara today in response to a question from Senator Datuk Razali Idris about the latest achievement of the ministry’s special task force in exploring opportunities to produce Covid-19 vaccines with other countries.
The NIBM, he said, had signed an LOI with the Cuban Embassy here in cooperation with the Finlay Vaccine Institute (BioCubaFarma) and the Cuban Center for Genetic Engineering and Biotechnology to access the Covid-19 vaccine developed there.
He said that MOSTI had also taken the initiative to engage with the Coalition for Epidemic Preparedness Innovations (CEPI) to enable Malaysia to gain access to vaccine development, technology transfer and new expertise for local researchers.
“Among the benefits for Malaysia of joining CEPI is the priority given to participating in preclinical and clinical testing of new vaccines each time a pandemic occurs.
“Malaysia will also have access to CEPI-sponsored research and development data on vaccine production, including vaccine research conducted by a group of researchers from the University of Oxford,” he added. -Named
[ad_2]
